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trointestinal tract. Here we report for the ﬁrst time the
highly unusual ﬁnding of an immature acanthocephalan
retrieved from a patient’s eye, where it had attached itself
by means of its thorny proboscis. As we were unable fully to
identify the species of worm, its provenance remains some-
what elusive. We speculate that the parasite was accidentally
transferred from the environment to the eye, possibly by the
patient’s own hands.
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Abstract
The present study aimed to identify a sub-group of inoperable
alveolar echinococcosis (AE) patients undergoing long-term
treatment with benzimidazole (BZM) who presented with an
evolution suggestive of a parasitocidal effect. An evolution com-
patible with parasite death was observed in ﬁve patients.
Keywords: Infectious diseases, alveolar echinococcosis, liver
disease, benzimidazoles, PET-CT
(a) (b)
FIG. 1. (a) Anterior end and proboscis of the
acanthocephalan. (b) Detail of the proboscis.
Bars: approximately 100 lm.
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Alveolar echinococcosis (AE) of the liver is a parasitic dis-
ease as a result of the intrahepatic development of Echinococ-
cus multilocularis larvae. The clinical picture resembles that of
a patient with a slow-growing malignant tumour [1].
Invasion of the bile ducts and vessels and necrosis in the
central part of the parasitic lesion leads to severe complica-
tions (e.g. cholangitis, liver abscesses, portal hypertension and
biliary cirrhosis), which can seriously affect the quality of life
of these patients and inﬂuence their chances of survival [2,3].
Complete surgical resection of the parasitic tissue increases
the chances of cure but, because of a long clinical latency,
many cases are diagnosed at an advanced stage and complete
surgical resection of the parasitic lesion can be performed in
only 35% of patients [4–6]. In patients with nonresectable AE,
long-term treatment with benzimidazoles (BZM), mebendaz-
ole or albendazole can reduce the 10-year mortality to <20%
[2,7]. However, this treatment is costly and could have
adverse effects in 5–10% of patients [8]. In addition, BZM are
potentially teratogenic, and oral contraception is required for
women of child-bearing age [9]. Although it is generally
accepted that BZM are parasitostatic, opinions remain divided
as to whether BZM may sometimes be parasitocidal and
could therefore be safely discontinued after years of treat-
ment in selected patients [10,11]. Unfortunately, no clinical,
biological or morphological parameters to assess the thera-
peutic efﬁcacy of treatment with BZM have been identiﬁed.
This is largely a result of the difﬁculty in predicting in vivo par-
asite viability. Recently, ﬂuorodeoxyglucose positron-emission
tomography (FDG-PET) has emerged as a reliable method for
discriminating between active and inactive AE lesions, allow-
ing the prospect of discontinuation of treatment with BZM in
patients showing no signs of parasite activity [11–14].
The present study aimed to describe a subgroup of
inoperable AE patients undergoing treatment with BZM
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with an evolution suggesting the parasitocidal effect of the
drug, namely disappearance of antibodies and imaging data,
obtained by computed tomography (CT) and FDG-PET, sug-
gestive of involution at the end of follow-up (Fig. 1).
The diagnosis of AE is based on morphological imaging
studies (CT or magnetic resonance imaging), serological
results and/or histopathological examination, as deﬁned by
the WHO [15]. Serum antibodies against Echinococcus anti-
gens were determined using an immunohistochemical assay
(Fumouze Diagnostics, Levallois-Perret, France), which was
considered to be positive when ‡80, using the Em2plus-
ELISA (Bordier Afﬁnity Products, Crissier, Switzerland)
according to the manufacturer’s recommendations [16,17].
Sequential follow-up consisted of repeated clinical examina-
tions, biological tests and imaging studies, including ultra-
sonography, CT and FDG-PET when available (from 2002
onward in our centre). The results of CT examinations at
diagnosis and at the end of follow-up were retrospectively
reviewed for all patients. All E. multilocularis lesions at
diagnosis were classiﬁed according to the PNM system
describing the anatomical localization and extent of AE:
hepatic localization/size of the parasite (P), absence/pres-
ence of involvement of neighbouring organs (N), and distant
metastases (M) [6,18]. In addition, the absence/presence of
calciﬁcations and the portion of the calciﬁed component
within the entire E. multilocularis lesion at diagnosis were
assessed. The size and structure of the parasitic lesion at
diagnosis were compared to those at time of speciﬁc anti-
bodies disappearance, aiming to identify reliable morphologi-
cal factors predictive of parasite death.
From the current cohort of 80 AE patients, we identiﬁed
ﬁve inoperable AE patients who presented an evolution
compatible with a parasite death under BZM (Table 1).
Symptoms at diagnosis were asthenia (n = 2), upper abdom-
inal pain (n = 3), and jaundice (n = 1). Symptomatic patients
(n = 3) improved after treatment with BZM was intro-
duced, and no clinical events occurred in any of the
patients during the entire follow-up period. All AE lesions
showed notable calciﬁcations (‡50% of AE lesion) at diagno-
sis. Moreover, all patients were M0 (no metastasis) at initial
imaging screening. The average duration of follow-up was
13.2 (range 8.5–15.4) years. Em2plus-ELISA became nega-
tive with a mean delay of 2.8 (range 0.5–5) years. At the
end of follow-up, a regression (n = 3) or a stabilization
(n = 2) of the lesions was observed at imaging screening.
None of the ﬁve patients showed any FDG-PET activity
despite the fact that BZM had previously been discontinued
in four cases after a mean time interval of 29.2 (range 6.8–
66) months.
Although no controlled studies have proven the efﬁcacy
of treatment with BZM in cases of AE, open studies have
suggested that these compounds are able to slow down the
growth of the parasitic mass [19]. Our own experience sup-
ports this view. Moreover, treatment with BZM led to a
regression of AE lesions, with no evidence of recurrence for
3 years in one case, and the serological tests became nega-
tive in all cases. In a previous study, Reuter et al. [12,13] dis-
continued treatment with BZM in 15 AE patients who
exhibited PET-negative lesions after an average of 46 months
of treatment. After a further 18 months of therapy, eight of
the 15 patients showed progression of the disease, deﬁned
as either newly-developed PET positivity (n = 6) or clinical
signs of progression (n = 2). In the present study, BZM was
discontinued according to PET evaluation, with no other cri-
teria. This further emphasizes the fact that PET negativity
alone is not enough to indicate parasite death.
In summary, long-term treatment with BZM appears to
have a parasitocidal effect in a sub-group of inoperable AE
patients. We hypothesized that BZM could be discontinued
when several ﬁndings were associated: disappearance of
speciﬁc antibodies, calciﬁed component of the AE lesion lar-
ger than 50% at diagnosis, and negative FDG-PET.
(a) (b) (c)
FIG. 1. Example of an alveolar echinococcosis (AE) patient with favourable evolution under treatment with benzimidazole (BZM) (patient 2). AE
lesion at diagnosis observed by computed tomography (CT) (a). AE lesion involution with extension of calciﬁed components surrounding the
lesion observed by CT (b). Absence of metabolic activity on ﬂuorodeoxyglucose positron-emission tomography performed after interruption of
treatment with BZM (c).
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Nevertheless, this decision to discontinue treatment
requires considerable caution, and careful sequential follow-
up should be maintained because reactivation of the
metacestode after interruption of treatment with BZM has
previously been reported [13]. In the future, additional new
reliable tools for detecting parasite viability should be used
to support the decision to discontinue AE treatment [11,20].
From now on, a more personalized approach to inoperable
AE patients undergoing long-term BZM therapy appears
conceivable, owing to the recent development of new tools
that are able to assess metacestode viability.
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